FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213053456> ?p ?o ?g. }

• W4213053456 abstract "Both modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in patients with pancreatic cancer, and are often used interchangeably as the standard of care. Preclinical studies often do not use these regimens, since administering these multiagent approaches can be difficult. In this study, we assessed the feasibility of administering these two chemotherapy regimens in spontaneous pancreatic tumors using KPC mice with the ultimate goal of advancing preclinical studies.KPC mice were created by breeding KrasLSL-G12D/+ to Trp53fl/fl;Ptf1αCre/+, resulting in KrasLSL-G12D/+;p53fl/+;Ptf1αCre/+ mice. At 14 weeks of age, mice were palpated for spontaneous tumor growth that was verified using ultrasounds. Mice with tumors under 15 mm in diameter were used. The mice were assigned to one of seven treatment regimens: 1 cycle of mFFX (FFX X1), 2 cycles of mFFX (FFX X2), 1 cycle of mFFXwith 40 Gy SBRT (FFX SBRT), 1 cycle of gemcitabine/nab-paclitaxel (GEM/AB X1), 2 cycles of gemcitabine/nab-paclitaxel (GEM/AB X2), 2 cycles of gemcitabine/nab-paclitaxel with 40 Gy SBRT (GEM/AB SBRT), or saline only (control).In total, 92 mice were included. The median OS in the FFX X2 group was slightly longer that the median OS in the FFX X1 group (15 days vs 11 days, P = 0.003). Mice in the GEM/AB X2 group had longer OS when compared to mice in the GEM/AB X1 group (33.5 vs 13 days, P = 0.001). Mice treated with chemotherapy survived longer than untreated control animals (median OS: 6.5 days, P < 0.001). Moreover, in mice treated with chemotherapy, mice that received 2 cycles of GEM/AB X2 had the longest survival, while the FFX X1 group had the poorest OS (P < 0.001). The addition of chemotherapy was associated with reduced number of myeloid and lymphoid cell types, except for CD4 + cells whose levels were largely unaltered only in tumors treated with gemcitabine/nab-paclitaxel. Lastly, chemotherapy followed by consolidative SBRT trended towards increased local control and survival.We demonstrate the utility and feasibility of clinically relevant mFOLFIRINOX and gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer." @default.
• W4213053456 created "2022-02-24" @default.
• W4213053456 creator A5007978793 @default.
• W4213053456 creator A5010272759 @default.
• W4213053456 creator A5013690559 @default.
• W4213053456 creator A5016467017 @default.
• W4213053456 creator A5040643325 @default.
• W4213053456 creator A5042435815 @default.
• W4213053456 creator A5048521277 @default.
• W4213053456 creator A5053516369 @default.
• W4213053456 creator A5071445059 @default.
• W4213053456 creator A5079075847 @default.
• W4213053456 creator A5082858580 @default.
• W4213053456 date "2022-02-16" @default.
• W4213053456 modified "2023-10-14" @default.
• W4213053456 title "Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model" @default.
• W4213053456 cites W1968812902 @default.
• W4213053456 cites W1975153720 @default.
• W4213053456 cites W2047318784 @default.
• W4213053456 cites W2104930742 @default.
• W4213053456 cites W2109351460 @default.
• W4213053456 cites W2115658806 @default.
• W4213053456 cites W2126663928 @default.
• W4213053456 cites W2127554019 @default.
• W4213053456 cites W2129176863 @default.
• W4213053456 cites W2129197203 @default.
• W4213053456 cites W2151253787 @default.
• W4213053456 cites W2210424760 @default.
• W4213053456 cites W2737789729 @default.
• W4213053456 cites W2746094882 @default.
• W4213053456 cites W2903623792 @default.
• W4213053456 cites W2920167237 @default.
• W4213053456 cites W2943249094 @default.
• W4213053456 cites W2949842359 @default.
• W4213053456 cites W3026142237 @default.
• W4213053456 cites W3119005666 @default.
• W4213053456 cites W3154258860 @default.
• W4213053456 cites W3158634056 @default.
• W4213053456 cites W3161080579 @default.
• W4213053456 cites W3166051227 @default.
• W4213053456 cites W3188058642 @default.
• W4213053456 cites W4225794093 @default.
• W4213053456 doi "https://doi.org/10.1186/s12885-022-09255-3" @default.
• W4213053456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35172762" @default.
• W4213053456 hasPublicationYear "2022" @default.
• W4213053456 type Work @default.
• W4213053456 citedByCount "3" @default.
• W4213053456 countsByYear W42130534562022 @default.
• W4213053456 countsByYear W42130534562023 @default.
• W4213053456 crossrefType "journal-article" @default.
• W4213053456 hasAuthorship W4213053456A5007978793 @default.
• W4213053456 hasAuthorship W4213053456A5010272759 @default.
• W4213053456 hasAuthorship W4213053456A5013690559 @default.
• W4213053456 hasAuthorship W4213053456A5016467017 @default.
• W4213053456 hasAuthorship W4213053456A5040643325 @default.
• W4213053456 hasAuthorship W4213053456A5042435815 @default.
• W4213053456 hasAuthorship W4213053456A5048521277 @default.
• W4213053456 hasAuthorship W4213053456A5053516369 @default.
• W4213053456 hasAuthorship W4213053456A5071445059 @default.
• W4213053456 hasAuthorship W4213053456A5079075847 @default.
• W4213053456 hasAuthorship W4213053456A5082858580 @default.
• W4213053456 hasBestOaLocation W42130534561 @default.
• W4213053456 hasConcept C121608353 @default.
• W4213053456 hasConcept C126322002 @default.
• W4213053456 hasConcept C126894567 @default.
• W4213053456 hasConcept C143998085 @default.
• W4213053456 hasConcept C2776694085 @default.
• W4213053456 hasConcept C2777148230 @default.
• W4213053456 hasConcept C2777292972 @default.
• W4213053456 hasConcept C2780140570 @default.
• W4213053456 hasConcept C2780210213 @default.
• W4213053456 hasConcept C2780258809 @default.
• W4213053456 hasConcept C2780259306 @default.
• W4213053456 hasConcept C526805850 @default.
• W4213053456 hasConcept C71924100 @default.
• W4213053456 hasConceptScore W4213053456C121608353 @default.
• W4213053456 hasConceptScore W4213053456C126322002 @default.
• W4213053456 hasConceptScore W4213053456C126894567 @default.
• W4213053456 hasConceptScore W4213053456C143998085 @default.
• W4213053456 hasConceptScore W4213053456C2776694085 @default.
• W4213053456 hasConceptScore W4213053456C2777148230 @default.
• W4213053456 hasConceptScore W4213053456C2777292972 @default.
• W4213053456 hasConceptScore W4213053456C2780140570 @default.
• W4213053456 hasConceptScore W4213053456C2780210213 @default.
• W4213053456 hasConceptScore W4213053456C2780258809 @default.
• W4213053456 hasConceptScore W4213053456C2780259306 @default.
• W4213053456 hasConceptScore W4213053456C526805850 @default.
• W4213053456 hasConceptScore W4213053456C71924100 @default.
• W4213053456 hasFunder F4320306422 @default.
• W4213053456 hasFunder F4320306536 @default.
• W4213053456 hasFunder F4320308129 @default.
• W4213053456 hasFunder F4320332161 @default.
• W4213053456 hasIssue "1" @default.
• W4213053456 hasLocation W42130534561 @default.
• W4213053456 hasLocation W42130534562 @default.
• W4213053456 hasLocation W42130534563 @default.
• W4213053456 hasLocation W42130534564 @default.
• W4213053456 hasLocation W42130534565 @default.
• W4213053456 hasOpenAccess W4213053456 @default.
• W4213053456 hasPrimaryLocation W42130534561 @default.

• next